about
Management of bleeding in patients treated with direct oral anticoagulantsDabigatran approaching the realm of heparin-induced thrombocytopeniaReversal of direct oral anticoagulants in hemophilia treatment: ASH meeting 2015Efficacy and safety of novel anticoagulants in the elderlyPlatelets are versatile cells: New discoveries in hemostasis, thrombosis, immune responses, tumor metastasis and beyond.Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the NetherlandsAntithrombotic Usage Patterns in the Era of New Oral Anticoagulant Options for Atrial Fibrillation.Individualising Anticoagulant Therapy in Atrial Fibrillation PatientsSpontaneous Intracerebral Hemorrhage: Management.Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases.Point-of-care coagulation monitoring: first clinical experience using a paper-based lateral flow diagnostic device.Reversal of dabigatran by idarucizumab: when and how?Apixaban to prevent stroke in patients with atrial fibrillation: a review.Idarucizumab: A Review as a Reversal Agent for Dabigatran.Neurocritical Care of Emergent Large-Vessel Occlusion: The Era of a New Standard of Care.Medical management of intracerebral haemorrhage.Major trauma in the older patient: Evolving trauma care beyond management of bumps and bruises.Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures.Approaches to prevent bleeding associated with anticoagulants: current status and recent developments.Reversal of Dabigatran with Idarucizumab.A Comparison of Oral Anticoagulant Use for Atrial Fibrillation in the Pre- and Post-DOAC Eras.The Use of Idarucizumab for Dabigatran Reversal in Clinical Practice: A Case Series.Cerebral Ischemic Reperfusion Injury Following Recanalization of Large Vessel Occlusions.Replacing warfarin with a novel oral anticoagulant: Risk of recurrent bleeding and stroke in patients with warfarin ineligible or failure in patients with atrial fibrillation (The ROAR study).The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran.Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.Management of Complications in Anticoagulated Patients with Atrial Fibrillation.Use of Idarucizumab for dabigatran reversal: Emergency department experience in two cases with subdural haematoma.Comment on: "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study".Direct Oral Anticoagulants in Dental Patients Including the Frail Elderly Population.Systemic thrombolysis and endovascular thrombectomy in severe acute ischemic stroke after dabigatran reversal with idarucizumab.
P2860
Q26740258-0114D43D-D399-490C-AC99-B0A1CDB3106EQ26744261-BD5B9C37-65DB-473F-B513-A1A6A16EC322Q28072261-C204383A-C3EE-4AA6-BBD4-10B0AF6FE9E3Q28079383-78FEB920-4CAD-4A6A-9936-75D1A7A9820FQ33432917-908348F2-82B3-44D9-9913-F289B1A82CF7Q36173045-E47FE872-FFFF-4F22-A027-C429C35D4F61Q37167694-13AD969F-2592-4723-8807-9930EF2035E9Q37235927-00515609-2459-4B80-B1E1-1534CE35FED7Q37640888-34254C69-70F6-4D30-9594-D8A25E95EEAAQ37680793-CFA48C20-4FDC-48E9-96F0-7FACC6EBF7ADQ38684860-81F18F5A-88A2-4502-893C-4BAC79F3BA28Q38831682-A4F9201C-C7D4-4233-AD77-AA3B93072878Q38876376-05FF80C2-970F-4B01-8D42-B0682348ED64Q38889351-B23C9C1E-8566-473B-91B8-5E0A794CD140Q38902528-AC2DD8DD-862C-4EB1-ACB8-0790D922FCADQ39010418-D8009303-5790-412D-B5EB-BAD563BE2AF6Q39271812-D12EC53E-CB25-4E1E-B2E2-CBDFA9A9040BQ39448172-EC47ED14-403B-4EB3-9424-71305D01CF5DQ39456319-A8A5C7D5-32BC-4D97-90C3-5488DFD70A6AQ39642830-986CF48B-7A52-40F4-8051-1FB8254F9B13Q39787308-1B9635E0-8AB9-4B7E-AD98-B17FF65A3B95Q47116446-578216A9-7657-4C04-8B37-C4EA3637BD31Q48035381-579FF90E-C9EB-4C79-B724-2D3B52B0DD62Q48152726-C6E4FD9D-2015-434A-ABA6-564E8563D2BBQ48252493-F55F363D-C8AE-49DD-AA6D-782A696C8507Q48375140-270877FD-BA97-4CAE-92E8-3E860BF81286Q49707565-FFF8FBBC-2E3C-47DB-B4F2-CF0F37EC42E4Q52592697-1BFEF0D3-B7F1-4BB4-946D-94CDDC9E659AQ53602855-DE5D9D83-3176-41C4-A1EE-56739BDB6552Q55050376-ACD429A3-2A11-49AD-A324-82A4731985E9Q55380077-9E4F4936-81EF-4E17-894E-955912900A4F
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Idarucizumab: The Antidote for Reversal of Dabigatran
@ast
Idarucizumab: The Antidote for Reversal of Dabigatran
@en
Idarucizumab: The Antidote for Reversal of Dabigatran
@nl
type
label
Idarucizumab: The Antidote for Reversal of Dabigatran
@ast
Idarucizumab: The Antidote for Reversal of Dabigatran
@en
Idarucizumab: The Antidote for Reversal of Dabigatran
@nl
prefLabel
Idarucizumab: The Antidote for Reversal of Dabigatran
@ast
Idarucizumab: The Antidote for Reversal of Dabigatran
@en
Idarucizumab: The Antidote for Reversal of Dabigatran
@nl
P2093
P3181
P1433
P1476
Idarucizumab: The Antidote for Reversal of Dabigatran
@en
P2093
Daniel J. Quinlan
Jeffrey I. Weitz
Joanne van Ryn
P304
P3181
P356
10.1161/CIRCULATIONAHA.115.019628
P407
P577
2015-12-22T00:00:00Z